Tezepelumab reduced CSU activity post-treatment through week 32, suggesting a delayed, sustained TSLP blockade effect.
Gillian McGovern
Advertisement
Articles by Gillian McGovern
The study examined the mechanisms of action associated with immune checkpoint inhibitor combination therapies.
Investigators used LIMS to classify melanoma samples as tumors and non-tumors.
According to study authors, this electrical communication between skin cells may have the potential for therapeutic implications.
Advertisement
Latest Updated Articles
Tezepelumab Shows Sustained Post-Treatment Benefit in Chronic Spontaneous Urticaria Despite Missed Primary EndpointPublished: March 19th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
